InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（5 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
5
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Lizzul Paul F., Directeur Médical. Officer active across 1 company, notably Anaptysbio, INC. In total, 20 reports have been logged. Split: 0 buy · 5 sells. Total volume traded: €401k. History available since 15 November 2021. The latest transaction was disclosed on 5 January 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Lizzul Paul F.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
8,525 股Common StockSEC:0001711462-26-000006:0
6,145 股Common StockSEC:0001711462-26-000004:0
4,219 股@ US$43.2624.3% 占其流量Common StockSEC:0001711462-26-000002:1
10,555 股Common StockSEC:0001711462-26-000002:0
1,500 股@ US$18.503.7% 占其流量Common StockSEC:0001711462-25-000003:0
1,500 股@ US$50.0010.0% 占其流量Common StockSEC:0001711462-25-000003:1
4,336 股@ US$14.609.6% 占其流量Common StockSEC:0001415889-25-001046:1
2,261 股@ US$15.305.2% 占其流量Common StockSEC:0001415889-25-001046:3
10,555 股Common StockSEC:0001415889-25-001046:0
6,145 股Common StockSEC:0001415889-25-001046:2
1,500 股@ US$18.503.9% 占其流量Common StockSEC:0001415889-24-023900:0
1,500 股@ US$38.678.1% 占其流量Common StockSEC:0001415889-24-023900:1
2,220 股@ US$38.9312.1% 占其流量Common StockSEC:0001415889-24-023550:1
6,000 股Common StockSEC:0001415889-24-023550:0
2,000 股@ US$18.505.2% 占其流量Common StockSEC:0001415889-24-021452:0
1,500 股@ US$18.504.0% 占其流量Common StockSEC:0001415889-24-019829:0
6,145 股0Common StockSEC:0001209191-24-001280:0
2,554 股@ US$21.817.9% 占其流量Common StockSEC:0001209191-24-001280:1
6,000 股Common StockSEC:0001209191-23-049810:0
964 股@ US$22.033.0% 占其流量Common StockSEC:0001209191-21-065178:0
20 条申报中的 20 条
About Lizzul Paul F.
Lizzul Paul F. is Directeur Médical and Chief Medical Officer at Anaptysbio, INC (XNAS). He has filed 20 disclosures in total, and across the sampled recent filings from 2021-11-17 to 2026-01-09, sales total EUR 400752, with the dominant transaction nature listed as Levée d'options.
